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Abstract
Background: The standard of care for neovascular age-related macular degeneration (nAMD) involves ongoing
intravitreal injections of anti-angiogenic drugs targeting vascular endothelial growth factor (VEGF). The most
commonly used anti-VEGF drugs are ranibizumab, bevacizumab and aflibercept. The main objective of the STAR
trial is to determine if stereotactic radiotherapy can reduce the number of anti-VEGF injections that patients with
nAMD require.
Methods/design: STAR is a multicentre, double-masked, randomised, sham-controlled clinical trial. It evaluates a
new device (manufactured by Oraya, Newark, CA, USA) designed to deliver stereotactic radiotherapy (SRT) to nAMD
lesions. The trial enrols participants with chronic, active nAMD. Participants receive a single SRT treatment (16 Gy or
sham) with a concomitant baseline intravitreal injection of 0.5 mg ranibizumab. Thereafter, they attend every month
for 24 months, and ranibizumab is administered at the visit if retreatment criteria are met. The primary outcome is
the number of pro re nata ranibizumab injections during the first 24 months. Secondary outcomes include visual
acuity, lesion morphology, quality of life and safety. Additional visits occur at 36 and 48 months to inspect for
radiation retinopathy.
The target sample size of 411 participants (randomised 2:1 in favour of radiation) is designed to detect a reduction
of 2.5 injections against ranibizumab monotherapy, at 90% power, and a significance level (alpha) of 0.025 (one-
sided two-sample t test). This gives 97% power to detect non-inferiority of visual acuity at a five-letter margin. The
primary analyses will be by intention to treat.
Discussion: The safety and efficacy outcomes will help determine the role of SRT in the management of chronic,
active nAMD.
Trial registration: International Standard Randomised Controlled Trial Number: ISRCTN12884465. Registered on 28
November 2014.
ClinicalTrials.gov: NCT02243878. Registered on 17 September 2014.
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Background
Age-related macular degeneration (AMD) is the leading
cause of loss of vision in the elderly in developed coun-
tries [1]. There are two forms of AMD: a ‘dry’ atrophic
form and a ‘wet’ neovascular form. Wet AMD is associated
with the formation of choroidal neovascularisation (CNV),
which leaks blood and fluid into and under the macula,
causing macular scarring and central vision loss. The over-
all prevalence of wet AMD is estimated to be 1.2%, increas-
ing to 2.5% in those aged 65 or older and to 6.3% in those
aged 80 years or older [2]. As the population ages, the
prevalence is projected to increase by one-third over 8 years
[2]. The standard of care for wet AMD involves intravitreal
injection of drugs targeting vascular endothelial growth
factor (VEGF), most commonly bevacizumab, ranibizumab
and aflibercept.
Ranibizumab (Lucentis®, Novartis, Frimley, UK), a
monoclonal fragment derived from the anti-VEGF anti-
body bevacizumab, was approved by the US Food and
Drug Administration in June 2006 for the treatment of
wet AMD. The Anti-VEGF antibody for the Treatment of
Predominantly Classic Choroidal Neovascularisation in
AMD (ANCHOR) study found that 96% of ranibizumab-
treated patients maintained or improved vision compared
with 64% of patients treated with photodynamic therapy
[3]. The Minimally Classic/Occult Trial of the Anti-VEGF
Antibody Ranibizumab in the Treatment of Neovascular
Age-Related Macular Degeneration (MARINA) study
demonstrated that 95% of ranibizumab-treated patients
experienced visual improvement or stabilisation compared
with 62% of sham-treated patients after 12 months [4].
Moreover, 34% of patients experienced 15 letter increases
in vision. In both the MARINA and ANCHOR studies,
patients received monthly ranibizumab injections [3, 4].
Current standard ranibizumab treatment commences with
monthly injections for 3 months, typically followed by
treatment on an as-needed (pro re nata, prn) basis if there
is evidence of disease activity.
Whilst generally safe and effective, anti-VEGF mono-
therapy entails a considerable burden of care for most
patients with neovascular AMD (nAMD), with regular
hospital review for the remainder of their life and re-
peated intraocular injections. Further, not all patients re-
spond fully, and some of those who do, fail to maintain
their response over time [5]. There is therefore an unmet
need for a more durable treatment that reduces the eco-
nomic cost of nAMD treatment and the considerable
burden faced by patients who require chronic anti-VEGF
monotherapy.
Theoretical, experimental and clinical evidence suggests
that low-dose external beam radiation is a useful therapy in
nAMD. Radiation has several potential benefits. First, it is
known to attenuate the inflammatory response and is there-
fore likely to attenuate the acute and delayed inflammatory
response that is thought to play a role in CNV reactivation
[6]. Second, radiation inhibits fibroblasts and thus reduces
scar formation, e.g. in its use for dermal keloids [7]. Scarring
is a key contributor to vision loss in nAMD. Third, radiation
leads to the death of rapidly dividing endothelial cells — the
main pathological component of CNV complexes [8].
The StereoTactic radiotherapy for wet Age-Related macu-
lar degeneration (STAR) trial investigates a new CE marked
device, manufactured by Oraya (Newark, CA, USA), that
uses radiation to treat nAMD, in a process called stereotac-
tic radiotherapy (SRT) [9–11]. Oraya’s SRT system is an
outpatient-based radiotherapy platform that provides
stereotactic application of low-energy X-ray radiation
to the retina [12–14]. The system uses three highly col-
limated beams of radiation that pass through the infer-
ior sclera to overlap at the macula, administered in a
single treatment session [15]. It uses a contact lens system
to hold the eye in the correct position for radiotherapy de-
livery, with eye tracking software. The SRT device delivers
radiation over a 4-mm treatment zone which receives at
least 90% of the intended dose [12, 13].
After favourable phase I data, the IRay plus Anti-VEGF
Treatment For Patients with Wet AMD (INTREPID)
study was initiated to further investigate SRT. This phase
II, randomised, double-masked, sham-controlled, dose-
ranging (16 and 24 Gy arms) trial recruited 230 patients. It
found that a single dose of SRT significantly reduces intra-
vitreal injections required over 1 and 2 years [16, 17]. In
terms of safety, SRT was shown to induce microvascular
abnormalities, but in only 1% of eyes was vision possibly
affected at the 2-year follow-up. A subgroup analysis
showed the best responders were those where the AMD
lesion had a greatest linear dimension <4 mm (corre-
sponding to the 90% isodose size) and when the lesion was
actively leaking at the time of SRT [18].
The STAR trial is a phase III study that builds on the
phase II INTREPID study, targeting patients with chronic
active nAMD, but it selectively recruits those thought
most responsive to SRT, namely those with active leakage
at enrolment and with lesions <4 mm [18]. It aims to de-
termine if SRT with prn ranibizumab is a safe and effective
treatment compared to prn ranibizumab monotherapy.
Methods/design
Overview
This phase III, double-masked, randomised controlled study
will randomise 411 participants to receive either 16-Gy or
sham SRT in a 2:1 allocation (favouring 16 Gy), with a con-
comitant baseline intravitreal injection of 0.5 mg ranibizumab.
Thereafter, participants will attend clinic for a review every
month (28 days) for 24 months, and ranibizumab will be ad-
ministered at the visit if defined retreatment criteria are met
(termed ranibizumab monthly prn). Two safety visits occur
subsequently, one at 36 months and the other at 48 months.
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Ethical approval was granted by the National Health
Service (NHS) Health Research Authority National Re-
search Ethics Service (NRES) Committee London — City
and East on 23 October 2013 (REC reference: 13/LO/
1207, IRAS project ID: 86810).
The trial is summarised in Fig. 1.
Eligibility
Inclusion criteria
The inclusion criteria are as follows:
 Participants must have neovascular AMD in the
study eye, for which they have received at least three
prior intravitreal injections of either bevacizumab
(Avastin), aflibercept (Eylea), ranibizumab (Lucentis)
or pegaptanib (Macugen).
 Participants must have received an anti-VEGF
injection in the study eye within 4 months prior
to enrolment.
 Participants must require treatment with anti-VEGF
therapy at the time of enrolment due to optical
coherence tomography (OCT) scan evidence of
subretinal fluid and/or cystoid macular oedema, and
have a macular volume that is greater than the
95th percentile of normal for the spectral domain
(SD)-OCT machines used in the investigational
sites.
 Participants must be at least 50 years of age.
Exclusion criteria
The exclusion criteria are as follows:
 Disciform scarring that involves the fovea, in the
study eye
 Visual acuity (VA) worse than 6/96 (24 Early
Treatment Diabetic Retinopathy Study [ETDRS]
letters) in the study eye
 Lesion size greater than 4 mm in greatest linear
dimension or greater than 2 mm from the centre of
the fovea to the furthest point on the lesion
perimeter, to include active choroidal neovascular
leakage, pigment epithelial detachment and
haemorrhage, as determined by fluorescein
angiography
Fig. 1 Summary of trial design
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 An axial length of less than 20 mm or greater than
26 mm, in the study eye
 Contraindication or sensitivity to contact lens
application, including recurrent corneal erosions, in
the study eye
 Type 1 or type 2 diabetes mellitus
 Retinopathy in the study eye
 Prior, current or anticipated treatment in the study
eye for AMD, other than anti-VEGF agents, including
submacular surgery, subfoveal thermal laser
photocoagulation, photodynamic therapy (PDT) or
transpupillary thermotherapy (TTT)
 Presence of an intravitreal device in the study eye
 Previous radiation therapy to the study eye, head or
neck with the exception of radio-iodine treatment
for hyperthyroidism, epimacular brachytherapy to
the non-study eye or Oraya SRT to the non-study
eye
 Inadequate pupillary dilation or significant media
opacities in the study eye, including cataracts, which
may interfere with visual acuity testing, the clinical
evaluation of the posterior segment or fundus
imaging
 Study eyes with CNV due to causes other than
AMD, including presumed ocular histoplasmosis
syndrome (POH), angioid streaks, multifocal
choroiditis, choroidal rupture and pathological
myopia (greater than 8 dioptres spherical
equivalent). Participants with retinal angiomatous
proliferation (RAP) or idiopathic polypoidal
choroidal vasculopathy (IPCV) are not excluded
 Known allergy to intravenous fluorescein,
indocyanine green or intravitreal ranibizumab
 Intraocular surgery or laser-assisted in situ
keratomileusis (LASIK) in the study eye within
12 weeks prior to enrolment
 Prior pars plana vitrectomy in the study eye
 Current participation in another interventional
clinical trial or participation in such a clinical trial
within the last 6 months
 Unwilling, unable or unlikely to return for scheduled
follow-up for the duration of the trial
 Women who are pregnant at the time of
radiotherapy
 Participants with an implantable cardioverter
defibrillator (ICD) or pacemaker implant (or any
implanted device) where the device labelling
specifically contraindicates patients undergoing X-
ray radiation
 Any other condition which, in the judgement of the
investigator, would prevent the participant from
granting informed consent or completing the study,
such as dementia and mental illness (including
generalised anxiety disorder and claustrophobia)
Randomisation
Once baseline assessments are complete and consent
has been obtained by trial-certified medical staff, partici-
pants will be randomised to SRT and sham in a 2:1 ratio.
Randomisation is at the patient level and is performed
using an online randomisation system set up by the King’s
Clinical Trials Unit (KCTU) at King’s College London. Ran-
domisation is stratified by national treatment centre with
variable block sizes to ensure that patients are allocated to
the two arms within each treatment centre in a 2:1 ratio.
The procedure is as follows: The patient travels from his/
her local recruiting site, having been determined as eligible.
Staff members at the national treatment centre then use
the online randomisation system to get an alphanumeric
code. This is entered into the Oraya machine, which will
then administer sham treatment or active treatment. The
person delivering the radiation/sham treatment does not
know which has been selected, as the machine fires up and
prepares a dose map in the same way for each treatment.
Outcome measures
Primary
The primary outcome will be the number of prn ranibizu-
mab injections during the first 24 months of the study.
Secondary (at 24 months)
Secondary outcome measures are the following:
 Mean ETDRS VA
 Percentage of participants losing <15 ETDRS letters
 Percentage of participants gaining ≥0 ETDRS letters
 Percentage of participants gaining ≥15 ETDRS letters
 Total lesion size by fluorescein angiography
 Total CNV size by fluorescein angiography
 Foveal thickness measured using OCT
 Health-related quality of life assessed using the
National Eye Institute 25-Item Visual Function
Questionnaire (VFQ-25) and the EuroQol EQ-5DTM
questionnaire
 Cost per quality-adjusted life year (QALY)
Patient recruitment and consent procedure
Potential participants will be identified from retinal clinics
at the trial sites and provided with a Research Ethics Com-
mittee (REC)-approved Patient Information Sheet. After
at least 24 hours, usually longer, they will be invited to at-
tend a screening visit if they wish to participate. Partici-
pants must sign an NHS REC-approved consent form
prior to any study-specific procedures.
Study treatments
Stereotactic radiotherapy
SRT will be provided in two or more UK national treat-
ment centres (NTCs). Participants will travel from their
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recruiting site to the NTC for SRT and then return to
their recruiting site for study follow-up. Participants will
receive a 16-Gy dose of radiation (or sham treatment)
delivered to the macula in a single session using the ro-
botically controlled SRT device, utilising three sequential
beams. Each beam deposits 5.3 Gy at the macula, via the
pars plana (Fig. 2). If it is not possible to obtain clear ac-
cess for all three beams, then it may, on occasion, be ne-
cessary to deliver radiation through two beams. The dose
of radiation will therefore be 8 Gy per beam, identical to
the dose delivered in each of the three beams used in the
24 Gy arm of the INTREPID study [16]. Treatment takes
about 10–20 minutes.
Sham treatment
Participants in the control group will undergo a pro-
cedure that is identical to active treatment, but the de-
vice will not deliver radiation. The device eye tracking
and simulated dose mapping appear identical to those
of the live treatment.
Ranibizumab treatment
All participants will receive a baseline intravitreal injec-
tion of 0.5 mg ranibizumab alongside SRT. Studies indi-
cate that SRT is more effective if given alongside anti-
VEGF therapy [11, 19]. Ranibizumab will be administered
in the NTC, immediately after SRT. After the initial ranibi-
zumab treatment, participants will be reviewed every
28 days in the recruiting site, and intravitreal 0.5 mg ranibi-
zumab will be administered at that visit if the Comparison
of AMD Treatments Trials (CATT) retreatment criteria
apply [20], which in summary are:
 The presence of fluid on the OCT (except those
eyes in which there has been no decrease in fluid
after three consecutive monthly injections)
 Subretinal or intraretinal haemorrhage
 Decreased visual acuity without another explanation
 Increased lesion size or the presence of leakage on
fluorescein angiography
Study assessments
Screening (day -14 to day 0)
All ocular assessments will be undertaken on both eyes:
 Demographic information
 Medical and ophthalmic history, including
medication use
 Blood pressure
 Best corrected ETDRS VA at 4 m (performed prior
to dilating eyes)
 Ophthalmic examination including slit lamp and
indirect ophthalmoscopy
 Intraocular pressure (IOP)
 Cataract assessment (Age-Related Eye Disease Study
[AREDS] 2008 criteria)
 Optical coherence tomography (OCT, see the
following paragraph)
 Fluorescein and indocyanine green angiography (see
the following paragraph)
 Fundus photography (see the following paragraph)
 Biometry
 Health-related quality of life and visual function
questionnaires
The OCT, fluorescein angiogram and fundus photo-
graphs are sent to the independent reading centre at base-
line and at months 12, 24, 36 and 48, but not at other
visits unless retinopathy is identified. Indocyanine green
angiography is only performed at baseline (Table 1).
Day 0 is defined as the day on which the patient suc-
cessfully enrols in the study. The measurements recorded
during screening constitute the baseline values for sub-
sequent comparison.
Fig. 2 a Computer-generated image showing the operator station (left) and SRT machine separated by a lead-lined glass window. b Image showing
the suction-coupled contact lens and position of radiotherapy beams passing through inferior sclera to converge on the macula (images courtesy
of Oraya)
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Stereotactic radiotherapy (day 0 to day 21)
SRT should be administered within 21 days of successful
screening (day 0 to 21). SRT and one dose of ranibizu-
mab will be delivered at the NTCs, as described above.
Monthly review
Participants will return to their recruiting site every 28 days
for 24 visits for measurement of ETDRS VA, slit lamp
examination of the anterior segment and fundus and OCT,
in the study eye. Fluorescein angiography will be under-
taken only if clinically indicated. The first monthly review
should be 28 days after the initial ranibizumab injection.
ETDRS VA and OCT examinations will be undertaken by
trial-certified staff, and equipment and ranibizumab will be
administered if the CATT retreatment criteria apply [20].
Investigators will record monthly central subfield thickness
with manual correction of any segmentation errors.
Months 12, 24, 36 and 48
At months 12, 24, 36 and 48 the following will be per-
formed on both eyes:
 ETDRS VA
 Ophthalmic examination
 IOP
 Cataract assessment (AREDS 2008 criteria)
 OCT sent to the reading centre
 Fluorescein angiogram and fundus photographs sent
to the reading centre
 Health-related quality of life and visual function
questionnaires
Table 1 Schedule of enrolment, interventions and assessments
Assessment Screening SRT with baseline
ranibizumaba
Monthly reviewb
(months 1–11)
Month 12 Monthly reviewb
(months 13–23)
Month 24 Month 36 Month 48
Visit window: Day 0 = day of
successful enrolment
Day -14 to 0 Day 0 to 21 ±7 days ±7 days ±7 days ±7 days ±14 days ±14 days
Informed consent X
Demographics X
Ophthalmic history X
Med. history/con meds X
Blood pressure X
ETDRS visual acuity X X X X X X X
Intraocular pressure X X X X X
Cataract assessment X X X X X
Biometry X
OCT (sent to reading centre) X X X X X
OCT (not sent to reading centre) X X X
Fundus photographs
(sent to reading centre)
X X X X X
Fluorescein angiography
(sent to reading centre)
X X X X X
Indocyanine green angiographyc
(sent to reading centre)
X
Stereotactic radiotherapy with
mandated baseline ranibizumaba
X
Ranibizumab injection if
required (prn)
X X X X X X
Health Economics questionnaires X X X X X X
EQ-5D and VFQ-25 patient
questionnairesd
X X X X X
Adverse events/ConMed
changes
X X X X X X
aThe baseline mandated ranibizumab injection should be given at the national treatment centres following stereotactic radiotherapy
bMonthly review entails review every 28 days rather than by calendar month. The first monthly review should be scheduled 28 ± 7 days after stereotactic
radiotherapy/baseline ranibizumab. It is preferable to allow at least 23 days between visits, as this is the minimum time between ranibizumab injections
cIndocyanine green may be omitted in centres that do not have indocyanine green capability, if pre-agreed by Sponsor
dA treatment satisfaction questionnaire will also be administered by the Sponsor, via telephone. The satisfaction questionnaire is undertaken by central staff, as
participants may feel more at liberty to discuss their level of satisfaction without concern that it will affect their local care
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The visits at months 36 and 48 are mainly designed to
detect any radiation induced-microvascular abnormal-
ities/radiation retinopathy.
Adverse events and safety reporting
An investigator who detects microvascular abnormalities
or signs of radiation retinopathy will forward fundus
photographs, angiography and OCT scans to the reading
centre. If the reading centre confirms retinopathy or de-
tects a case of retinopathy during routine image review,
it will forward the images to a Retinopathy Evaluation
Committee. The Retinopathy Evaluation Committee will
consist of experts in reading fluorescein angiograms and
experts in the clinical characteristics of radiation retinop-
athy. The Retinopathy Evaluation Committee will decide
by majority vote whether or not radiation retinopathy or
radiation-related microvascular abnormalities are present.
The committee will be the final arbiter as to whether or
not radiation retinopathy/microvascular abnormalities are
present, but it may review its decision if new, relevant,
clinical information emerges for a particular case.
Sample size calculations
If SRT produces a 25% reduction, group sample sizes of
248 and 124 (ratio: 2:1) achieve 90% power to detect a dif-
ference of 2.5 injections between the null hypothesis that
both group means are 10 injections and the alternative hy-
pothesis that the mean of the active treatment group is 7.5
injections, with a standard deviation (SD) of 7 for both
and a significance level (alpha) of 0.05 (two-sided) using a
two-sample t test. A 2:1 ratio adds only 42 patients but
boosts recruitment and safety data.
We expect VA in the SRT group to be non-inferior com-
pared to the control group. The SD of the mean change in
VA was estimated as 12 letters from INTREPID. Group
sample sizes of 248 and 124 achieve 97% power to detect
non-inferiority in the mean changes in VA using a one-
sided, two-sample t test assuming an SD of 12 for both
groups. The margin of equivalence is 5 letters. The true
difference between the means is assumed to be 0. The sig-
nificance level (alpha) of the test is 0.025.
In the INTREPID study, 2.2% of the randomised popula-
tion were lost to follow-up by year 1. Year 2 data are not rep-
resentative, as INTREPID had minimal review in year 2. The
CABERNET study had 93% of data available for analysis at
the end of year 2. We anticipate a 10% loss to follow-up over
2 years for STAR, so we aim to recruit 274 participants in
the active arm and 137 in the control arm (total 411). Sam-
ple size calculations were performed using PASS software.
Justification for parameters used in the sample size
calculations
The INTREPID study (ClinicalTrial.gov identifier:
NCT01016873) compared patients treated with low-
voltage X-ray, external-beam SRT plus ranibizumab
prn to patients treated with sham SRT plus ranibizumab
prn. Since INTREPID studied anti-VEGF-experienced pa-
tients, the results of that study are more relevant to the
STAR population than the results of CATT, which studied
anti-VEGF-naïve participants. Participants in INTREPID
were randomised to 16 Gy plus ranibizumab prn, 24 Gy
plus ranibizumab prn or sham radiotherapy (either 16 Gy
or 24 Gy) plus ranibizumab prn. The mean changes in
ETDRS VA at 12 months (±SD) were –0.28 ± 8.77, 0.40 ±
10.33 and –1.57 ± 11.90, respectively. The pooled SD
across all groups is therefore 10.4, with approximate 95%
confidence limits of 9.6 and 11.5. For power calculations
for STAR, the assumed SD of the mean change in VA is
12 letters.
The treatment arm of the present study (STAR) will re-
ceive 16-Gy SRT, as used in the INTREPID study. Both
arms will receive ranibizumab prn, as used in the CATT
trial. The primary outcome is the ranibizumab re-injection
rate over 2 years. CATT reported a mean (±SD) of 6.9 ± 3.0
ranibizumab retreatments to the end of year 1 and 12.6 ±
6.6 to the end of year 2. The year 2 retreatment rate is most
relevant to the STAR control group, which recruits patients
with previously treated disease (CATT participants were
treatment-naive at enrolment). The year 2 CATT retreat-
ment was calculated to be 5.7 injections (12.6 – 6.9), so
we might expect our control group to receive twice this
amount (11.4) over two years. As CATT was under-
taken in the USA, to allow more conservative assumptions
in case the injection rate is lower in the UK, we assume
the injection rate to be 10 injections over 2 years in our
control group, with an SD of 7 (based on INTREPID data
which showed the SD was 69% of the mean). A 25% reduc-
tion in the number of injections is thought to be clinically
and economically meaningful. Notwithstanding the fact
that the second year of INTREPID was primarily designed
to assess safety and not efficacy, this figure also matches
the 25% reduction in the injection rate in the 2 year results
of INTREPID, comparing the combined radiotherapy arms
to the sham arm (Jackson et al. [17, 18]).
Proposed timescale
The trial started in December 2014 and is projected to
end in October 2022, with a trial duration of 95 months.
The duration of each patient’s participation is monthly
for 24 months with additional safety visits at months 36
and 48.
Statistical analyses
In this section we summarise the statistical analysis. Full
details are provided in our Statistical Analysis Plan.
Baseline characteristics of each group will be summarised
as mean and SD for continuous variables with median and
interquartile range for highly skewed data, and count and
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percentage for categorical variables. No significance testing
on baseline variables will be performed.
The baseline characteristics will include patient demo-
graphics, randomisation stratifiers, ophthalmic history,
medical history, ETDRS visual acuity and other baseline
(screening) clinical measures. This will allow an assess-
ment of whether there is clinically important imbalance
in any variables.
The main statistical analyses will be conducted accord-
ing to intention to treat and will estimate the difference in
mean outcome between patients randomised to SRT and
sham by intention to treat at 24 months. Group difference
estimates and associated 95% confidence intervals will be
reported. Previous work (CATT and INTREPID) has sug-
gested that the number of injections is approximately nor-
mally distributed. In this case, a multiple linear regression
analysis will be used to assess the treatment effect with ad-
justment for the baseline stratification factor (treatment
centre). The analysis will not include the initial mandated
ranibizumab treatment, as it is administered to all partici-
pants and does not reflect the effect of SRT or sham treat-
ment. The treatment effect is evaluated at a two-sided
0.05 significance level. In the event that the number of in-
jections is not normally distributed, a data transformation
will be used to give normally distributed residuals. In the
unlikely event that no transformation is possible, analysis
will be based on a non-parametric approach, a stratified
Wilcoxon-Mann-Whitney (WMW) test (the van Elteren
test), adjusted for the baseline stratification factors and
the median difference with 95% confidence interval calcu-
lated by the (stratified) Hodges-Lehmann estimation.
The change in visual acuity (VA) will be formally tested
statistically for non-inferiority. The change in VA in the
SRT arm compared to the change in VA in the control
arm from baseline to month 24 will be analysed by using a
multiple linear regression model with adjustment for the
baseline stratification factor (treatment centre) and the
baseline VA score. Multiple linear regression will be used
rather than repeated measure analysis, because although
there will be 24 monthly visits for patients in the trial, the
focus of interest is the mean changes in VA from baseline
to month 24.
Data from the other efficacy outcomes will be sum-
marised. Statistical analysis of these outcomes will be
descriptive, with differences and 95% confidence inter-
vals. There will be no correction for multiple testing. Mean
vision change and mean OCT thickness will be plotted
against time (24 monthly visits over 2 years) as sum-
mary measures showing vision change over time and
OCT thickness over time.
Subgroup analyses of number of injections, mean VA
and OCT thickness (as a forest plot) will be conducted
for pre-specified subgroups defined by the following key
variables. All subgroup effects will be tested by fitting an
interaction factor in the model so that differences be-
tween subgroups will only be confirmed if the test for
interaction is statistically significant.
1. Total angiographic lesion size, as per reading centre
evaluation (above and below the median)
2. Greatest distance of the lesion from the foveal
centre, as per the reading centre evaluation
3. Angiographic lesion type per reading centre:
a. Type 1 (occult)
b. Type 2 (classic)
c. Type 3 (retinal angiomatous proliferation [RAP])
d. Mixed (minimally classic)
e. Idiopathic polypoidal choroidal vasculopathy
(IPCV)
4. OCT macular volume per reading centre (above and
below median)
5. Baseline vision in ETDRS letters (above and below
median)
6. Duration of disease (above and below median)
7. Number of prior anti-VEGF injections excluding
that given at baseline (above and below median)
8. Presence or absence of vitreomacular adhesion on
OCT, as per reading centre
9. Lens status (phakic or pseudophakic)
To address any missingness that occurs, we will con-
duct a sensitivity analysis of the primary outcome that is
adjusted for any factors shown to be different between
those present and those with full primary outcome data.
The number of patients who have not completed their
full treatment protocol is expected to be few, but will be
noted. In addition to the primary intention-to-treat analysis,
the effect of actually receiving treatment as defined in the
protocol will also be estimated by comparing the two arms
in just those who have received the full protocol.
Adverse events (AEs), adverse reactions, serious ad-
verse events and serious adverse reactions will be sum-
marised as counts and percentages with 95% confidence
intervals by trial arm. Where patients have not received
the allocated treatment, this will be noted in reporting
AEs so that the denominator for AEs is the number who
actually received each treatment.
Interim analysis
The usual rationale for an interim analysis is to consider
stopping the treatment (or the trial). However, as SRT is
given at baseline, it is not possible to subsequently stop
treatment. As such, we elected not to include an interim
analysis. The Data Monitoring Committee will regularly
examine the recruitment rate and data completeness and
will monitor safety, and the committee will recommend
whether the study should continue, stop, be suspended
or be modified, based on their findings.
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Economic evaluation
The health economic component of STAR will estimate
the relative cost-effectiveness of SRT compared to no SRT
and help determine whether SRT provides value for money
for the National Health Service. The main outcome meas-
ure will be quality of life, which will be used to calculate a
cost per QALY gained for SRT plus ranibizumab versus
ranibizumab alone.
Participants will complete the National Eye Institute
25 Item Visual Function Questionnaire (VFQ-25) [21] and
the EuroQoL EQ-5D [22] at enrolment and then yearly
until the study ends at month 48. This provides some indi-
cation of the baseline quality of life (in terms of visual
function) and a change in response to treatment of the
population compared on a common scale with other eye
trial adverse populations. The EQ-5D, a generic quality of
life questionnaire, will allow comparison of the study re-
sults against other (non-vision) health care interventions.
The base case analysis will take an NHS, personal and
social services perspective in accordance with National In-
stitute for Health and Care Excellence (NICE) guidance
[23, 24]. Since there is no Health Research Group (HRG)
code specific to intravitreal injection or AMD monitoring,
we will use microcosting estimates of the cost of ranibizu-
mab injections and associated monitoring that were col-
lected previously within the Inhibition of VEGF in Age-
related choroidal Neovascularisation (IVAN) trial [25]. This
costing work will be replicated to estimate the cost of ad-
ministering SRT alongside ranibizumab in routine clinical
practice. The number of ranibizumab injections, monitor-
ing consultations and ocular imaging procedures (angiog-
raphy and OCT) will be collected on standard trial forms.
At each study visit, participants will be asked to provide
data on all eye-related hospital admissions and contacts
with medical professionals or eye clinic liaison officers and
the reasons for such admissions and contacts, in addition
to any residential care, low vision aids and personal care
received.
A sensitivity analysis including only costs associated with
the study eye or expected adverse events will be conducted.
Data on all hospital admissions and outpatient consulta-
tions between randomisation and the end of the efficacy
study will also be collected from Hospital Episode Statistics
to ensure that costs are not underestimated by participant’s
recall, missed appointments and/or withdrawal from the
study. Analysis of costs and cost-effectiveness will follow
standard NICE guidelines [24]. We anticipate using boot-
strapping to estimate the uncertainty around incremen-
tal costs and QALYs, which will be presented as cost-
effectiveness acceptability curves.
Trial organisation and monitoring
Trial Management Committee
The Trial Management Committee consists of:
Mr Timothy Jackson, Chief Investigator, Consultant
Ophthalmic Surgeon, King’s College London, London,
UK
Mrs Riti Desai, Clinical Trials Manager, King’s College
Hospital, London, UK
Ms Joanna Kelly, Strategic Data Management Lead,
King’s Clinical Trials Unit, King’s College London, UK
Ms Caroline Murphy, Operational Director, King’s
Clinical Trials Unit, King’s College London, UK
Dr Yanzhong Wang, Senior Lecturer in Medical Statis-
tics, King’s College London, UK
Ms Beverley White-Alao, Trial Management Strategic
Lead, King’s Clinical Trials Unit, King’s College London, UK
Trial Steering Committee
The Trial Steering Committee consists of:
Mr Richard Wormald, Cochrane Eyes and Vision Group,
International Centre for Eye Health, London School of Hy-
giene and Tropical Medicine, London, UK (independent
voting clinical Chair)
Prof. Winfried Amoaku, Associate Professor and Reader
in Ophthalmology and Visual Sciences, University of Not-
tingham, UK (independent voting clinician)
Ms Clare Bailey, Consultant Ophthalmic Surgeon, Bristol
Eye Hospital, Bristol, UK (independent voting clinician)
Mr Timothy Jackson, Consultant Ophthalmic Surgeon,
King’s College London, London, UK (voting clinical Chief
Investigator)
Mr Luke Membrey, Consultant Ophthalmic Surgeon,
Maidstone Hospital, Kent, UK (non-voting Principal In-
vestigators’ representative)
Mr Barnaby Reeves, Professor of Health Services Re-
search, University of Bristol, Bristol, UK (non-voting trialist)
Mr Mandeep Sagoo, Consultant Ocular Oncologist, St
Bartholomew’s Hospital, London, UK (independent vot-
ing clinician)
Dr Yanzhong Wang, Senior Lecturer in Medical Statis-
tics, King’s College London, London, UK (voting Trial
Statistician)
Prof. Robert West, Professor of Biostatistics, Leeds In-
stitute of Health Sciences, Leeds, UK (independent vot-
ing statistician)
Ms Cathy Yelf, Head of External Relations, Macular
Society, London, UK (non-voting Lay Representative)
Data Monitoring Committee
The Data Monitoring Committee consists of:
Prof. Craig Ramsay, Statistician, Health Services Re-
search Unit, University of Aberdeen, UK
Prof. Paulo Stanga, Consultant Ophthalmologist and
Vitreoretinal Surgeon, Manchester Royal Eye Hospital,
Manchester, UK
Prof. Heinrich Heimann, Consultant Ocular Oncologist,
Royal Liverpool University Hospital, Liverpool, UK
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Key protocol amendments
The definition of the minimum OCT macular volume re-
quired for inclusion changed from the 95th percentile of
normal to defined values for each of the machines in use
across sites. Following amendment, the minimum
macular volume for the Heidelberg Spectralis machine
was 8.15 mm3, Topcon 3D-OCT 7.53 mm3, Optovue
6.14 mm3, and Zeiss Cirrus 10.3 mm3. A minimum macu-
lar volume formed part of the eligibility criteria, as a sub-
group analysis of the INTREPID study found macular
volume to be a key driver of outcome [18]. However, IN-
TREPID used an older, time-domain, OCT machine (Stra-
tus, Carl Zeiss Meditec, Cambridge, UK). The conversion
between Stratus OCT and the new SD-OCT machines
used in STAR was initially handled via each machine’s
normative database or published values, but the amend-
ment reduced the macular volume threshold to one we
believe to more closely match the INTREPID subgroup
threshold, based on discussions with machine manufac-
turers and our own data collection in patients with wet
AMD.
Initially, patients likely to require cataract surgery within
2 years of enrolment were excluded, but this exclusion cri-
terion was removed, as the emerging literature suggested
that stereotactic radiotherapy does not cause cataracts. We
relaxed the requirement that participants need to have had
an anti-VEGF injection within 3 months of enrolment to
4 months, to facilitate recruitment of an increasing propor-
tion of patients receiving aflibercept, who typically attend 2
monthly rather than monthly. We made small edits to clar-
ify the measurement of lesion size and distance of the lesion
to the fovea. Finally, to expand the number of sites, we
removed the requirement to undertake a baseline in-
docyanine green (ICG) angiography for sites without
ICG capability.
Discussion
AMD is the leading cause of blindness in developed na-
tions, and the incidence is projected to increase as the
population ages [26]. Wet AMD is treated with repeated
intravitreal anti-VEGF injections from the point of diagno-
sis. Whilst these injections have a favourable safety profile,
with visual outcomes far better than the natural history,
the treatment is burdensome and expensive, and is
associated with small but repeated risks of injection-
related complications.
A randomised, double-masked, sham-controlled phase II
study suggests that SRT may reduce the burden of nAMD
treatment by significantly reducing the number of injec-
tions that patients require [16, 17]. STAR is a phase III
randomised, sham-controlled, double-masked clinical trial
that evaluates the safety and efficacy of SRT. It targets
those patients thought to be most responsive to SRT, to
test the hypothesis that SRT reduces the frequency of
ranibizumab injections. A 2:1 ratio was selected to encour-
age enrolment, on the assumption that many of those
wishing to join the trial did so hoping to receive the new
treatment. It will also provide long-term safety data using
specialised imaging to look for collateral damage from ra-
diation, which previous studies suggest can be subtle and
with delayed onset.
The risk of bias is thought to be low, as the SRT device
produces very effective masking for the participant and op-
erator, such that all subsequent observations are concealed
to treatment allocation. One challenge of the trial is that
radiation damage can be very subtle, and sometimes rela-
tively non-specific. In the INTREPID study of SRT, only
two cases were initially detected by examining clinicians,
and most were instead detected by a reading centre, using
specialised imaging (fundus photographs with fluorescein
angiography). Although most cases of microvascular ab-
normality occurred outside the fovea and therefore did not
affect vision, some did involve the fovea and it can be diffi-
cult to determine if any loss of VA is due to radiation or
the underlying nAMD process. To deal with this uncer-
tainty, an independent expert committee will adjudicate
cases, but it is recognised that a definitive conclusion may
not be reached in all cases of suspected microvascular
abnormality.
If STAR demonstrates that SRT is safe and effective,
then it has the potential to change the treatment land-
scape and reduce the burden of treatment faced by the
growing number of people with wet AMD.
Trial status
At the time of manuscript submission, the recruitment
to the STAR trial is ongoing.
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